At the time of writing, Kiniksa Pharmaceuticals Ltd [KNSA] stock is trading at $20.89, up 3.62%. An important factor to consider is whether the stock is rising or falling in short-term value. The KNSA shares have gain 4.87% over the last week, with a monthly amount glided 14.65%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, February 2024, Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024. In a post published today on Yahoo Finance, Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2023 financial results and recent portfolio execution.
From an analyst’s perspective:
Kiniksa Pharmaceuticals Ltd [NASDAQ: KNSA] stock has seen the most recent analyst activity on June 29, 2020, when BofA Securities reiterated its Buy rating and also boosted its price target to $40 from $25. Previously, BofA/Merrill started tracking the stock with Buy rating on April 01, 2020, and set its price target to $25. On March 11, 2019, Barclays initiated with a Overweight rating and assigned a price target of $26 on the stock. Wedbush reiterated its Outperform rating and increased its price target to $33 on December 12, 2018. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $33 as its price target on June 19, 2018.
For the past year, the stock price of Kiniksa Pharmaceuticals Ltd fluctuated between $10.29 and $20.94. Kiniksa Pharmaceuticals Ltd [NASDAQ: KNSA] shares were valued at $20.89 at the most recent close of the market.
Analyzing the KNSA fundamentals
According to Kiniksa Pharmaceuticals Ltd [NASDAQ:KNSA], the company’s sales were 248.75M for trailing twelve months, which represents an -32.37% plunge. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.10 points at the first support level, and at 19.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.39, and for the 2nd resistance point, it is at 21.90.
Kiniksa Pharmaceuticals Ltd [KNSA] reported earnings per share of -$0.2 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.17/share, meaning a difference of -$0.03 and a surprise factor of -17.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were $0.21 per share as compared to estimates of -$0.17 per share, a difference of $0.38 representing a surprise of 223.50%.
Ratios To Look Out For
It is important to note that Kiniksa Pharmaceuticals Ltd [NASDAQ:KNSA] has a current ratio of 4.79. On the other hand, the Quick Ratio is 4.31, and the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 5.91, the price to book ratio is 3.63.
Transactions by insiders
Recent insider trading involved Ragosa Mark, CHIEF FINANCIAL OFFICER, that happened on Jan 03 when 12000.0 shares were sold. CHIEF ACCOUNTING OFFICER, Megna Michael R completed a deal on Jan 02 to sell 16670.0 shares. Meanwhile, CHIEF ACCOUNTING OFFICER Megna Michael R sold 9316.0 shares on Dec 19.
